{"name":"Merit E. Cudkowicz, MD","slug":"merit-e-cudkowicz-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOZVNNMndYbkdwN2UzM1JsTGw1eHpCVzBXM2lUVFVrLWFzYXduX3JGY24wbWlsMWFtS01qWnJLdGtKN0QyYXF6UmdqRENtNUV3VUV6Z3NvVU10NU9QUHdsZHFlUUhPLXlPNTd2Nmk0MTB5aWNXdmlQeDhfckF2bGFkZmQ3bU4tNHBSa1NfSGZDb2pST3M4YjhwOXdPUFhMc3lObWFHNkdBYmpxRkE1VlFrY01HMUpnTVVBSVoxYTBBd1M1bm9HYUNj?oc=5","date":"2025-04-06","type":"pipeline","source":"Healio","summary":"Merit E. Cudkowicz, MD, MSc, receives lifetime award for ALS research: ‘I'm not done yet’ - Healio","headline":"Merit E. Cudkowicz, MD, MSc, receives lifetime award for ALS research: ‘I'm not done yet’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQdjJIeEZXVXVOTWUzZXRhTEw4aFhqaEN2dnBIMG1aczl6TWJFOUdfTEJnZlJWYVZKNkViNm5pc1BpTnlvb2ZwNzhrQWI1OE9NTGJxVnhEVEpOUW5nRUNKS3NoWnBVNnRRNFJBeEVzUktXQkplM3Q0SGF6NEh1cjJndW5kell4MFIxVV9WNnRvemUtdC1kOWREMzFzVVNVZU1QQjRud1NoSUI4U2xO?oc=5","date":"2025-02-24","type":"trial","source":"Medscape","summary":"ALS Trials Fail to Meet Key Endpoints…But It’s Still a Win and Here’s Why - Medscape","headline":"ALS Trials Fail to Meet Key Endpoints…But It’s Still a Win and Here’s Why","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBheUFTcTc3TGxLM1J4LWFnaV9BMDVTbFEzZHRqVjFJdDg1TFE3V0RkX2htZEVacjZack8xUzlzWlFqcXRKcHA5MFV2V01SYW94UFhNbkxCQWxCTlFIRmdORnN1dHR4ajdnUVE?oc=5","date":"2023-06-21","type":"pipeline","source":"Neurology® Journals","summary":"Association of Polyunsaturated Fatty Acids and Clinical Progression in Patients With ALS - Neurology® Journals","headline":"Association of Polyunsaturated Fatty Acids and Clinical Progression in Patients With ALS - Neurology® Journals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBuOThDbDQ0UXVJNU9iemYtU1AtMnduR2w2UmNxT2FvSnN3T2xnZ0FfVVRUUGpsX3BmbndiQ0dsUFhscGd2OVp4eGE1NFNESlJjRVhhcFZVSjM0eUd1OGltcDVlTnBtZXpsS3c?oc=5","date":"2023-02-25","type":"trial","source":"Wiley Online Library","summary":"Randomized trial of inosine for urate elevation in amyotrophic lateral sclerosis - Walk - 2023 - Muscle & Nerve - Wiley Online Library","headline":"Randomized trial of inosine for urate elevation in amyotrophic lateral sclerosis - Walk - 2023 - Muscle & Nerve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE1FUDhnSENnQlU2dzNNdHdIbmpjN1d4OTRnUjFDMFFjb09naEpUZXMtN2tWM21lOUJIS3k5Q1Y1R0FzMmNXOXpyV2lBMFk3ZlZrSzEtZ1pmVE9fZGEtX0FRUQ?oc=5","date":"2022-09-21","type":"trial","source":"NEJM","summary":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS - NEJM","headline":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE9mYk5xZmpRYUJ3TXVtV0tpcTNjazlFNE5tSTBHVWJPU0NWQVc5NGg3OENpTkRsMmdUZVRjMUMwdTZuaWQ0cVAwdDhOQm1JYlBKRUZlQ2ExU1BUdWluQWZXa25vaF82NzFhTXc?oc=5","date":"2022-05-04","type":"trial","source":"Wiley Online Library","summary":"Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes - Wiley Online Library","headline":"Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9NcGpsbGt2Q19IYUNHZGp4UHdoSTN2QzJiVUJWYkJJZkswSGZDUUo0TG5sVUFFRWk1cWJhSHZKT2JCcTVMTTR3Wnd4b3hHcVhtRk8yNnlUTUhqU0xMU3hmeA?oc=5","date":"2020-07-08","type":"trial","source":"NEJM","summary":"Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS - NEJM","headline":"Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFByNUNXSkZvd1lscnp2akFmb1AtR3EtblFidEpDZmZXVTdPaXRlclRIMXdCM2ItemEwSHJoRlhnNHRvWHBqS1Bta29LWTU1R2RBTGlQVXRlNWRUUW9Dbm93?oc=5","date":"2018-08-29","type":"trial","source":"NEJM","summary":"Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis - NEJM","headline":"Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOcHQ0UXdPTXRhc3lYOEplc3hkV1Z1SnFNRGQ4aVpJY1NoQmVrVXRINEh1Sm5qT2VMX1lWbmlfMm5CZG5KbVJBZEx4LTFTSjJEUTNYZmo3LTVBRXZ4QlpEMW1pTXRoWU1mZWxVS0JKaGd6MWY0QU9pS0d6LXFiaUlKOGpOZw?oc=5","date":"2018-08-27","type":"pipeline","source":"NeurologyLive","summary":"Improvements in ALS Treatment Point to a Positive Future - NeurologyLive","headline":"Improvements in ALS Treatment Point to a Positive Future","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}